Sökning: WFRF:(Johansson Mikael)
> (1995-1999)
> Johansson Staffan >
A randomized prospe...
A randomized prospective study comparing long-term intravesical instillations of mitomycin-c and BCG in patients with superficial bladder carcinoma
-
Lundholm, Carl (författare)
-
- Norlen, Bo Johan (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Urology
-
Ekman, Peter (författare)
-
visa fler...
-
- Johansson, Staffan (författare)
- Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi
-
Lagerkvist, Mikael (författare)
-
Lindeborg, Torsten (författare)
-
Olsson, Jan Olov (författare)
-
Tveter, Kjell (författare)
-
Wijkstrom, Hans (författare)
-
Westberg, Ronny (författare)
-
- Malmstrom, Per-Uno (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Urology
-
visa färre...
-
(creator_code:org_t)
- 1996
- 1996
- Engelska.
-
Ingår i: Journal of Urology. - 0022-5347 .- 1527-3792. ; 156:2, s. 372-376
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- PURPOSE: We compared the efficacy and toxicity of long-term mitomycin C versus bacillus Calmette-Guerin (BCG) instillation in patients at high risk for recurrence and progression of superficial bladder carcinoma. MATERIALS AND METHODS: Our randomized comparison study included 261 patients with primary dysplasia, or stage Tis, stage T1, grade 3 and multiple recurrent stage Ta/T1, grade 1 or 2 disease. Mitomycin C (40 mg.) or Pasteur strain BCG (120 mg.) was instilled weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2. RESULTS: After a median followup of 39 months 49% of the patients given BCG and 34% given mitomycin C were disease-free (p < 0.03), compared to 48 and 35%, respectively, of those with stage Ta or T1 disease, and 54 and 33%, respectively, of those with dysplasia or stage Tis tumor. Tumor progressed in 13% of patients, with no statistically significant difference observed regarding progression between the mitomycin C and BCG groups. Side effects were more common after BCG instillation, with 5 cases of severe side effects compared to 1 in the mitomycin C group. Treatment was stopped due to toxicity in 10% of the patients. CONCLUSIONS: The majority of patients tolerated long-term intravesical therapy well. BCG instillation was hampered by more frequent side effects. BCG was superior regarding recurrence prophylaxis, since patients given BCG had fewer recurrences and a significantly longer time to treatment failure compared to those treated with mitomycin C. No statistically significant difference was observed regarding progression.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lundholm, Carl
-
Norlen, Bo Johan
-
Ekman, Peter
-
Johansson, Staff ...
-
Lagerkvist, Mika ...
-
Lindeborg, Torst ...
-
visa fler...
-
Olsson, Jan Olov
-
Tveter, Kjell
-
Wijkstrom, Hans
-
Westberg, Ronny
-
Malmstrom, Per-U ...
-
visa färre...
- Artiklar i publikationen
-
Journal of Urolo ...
- Av lärosätet
-
Uppsala universitet